• Barosi, G. & Marchetti, M. (2000) The clinical utility of epoetin in cancer patients: a matter of perspective. Haematologica, 85, 449450.
  • Beguin, Y. (2002) Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica, 87, 12091221.
  • Besarab, A., Reyes, C.M. & Hornberger, J. (2002) Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. American Journal of Kidney Disease, 40, 439446.
  • Bunn, H.F. (2002) Drug-induced autoimmune red-cell aplasia. New England Journal of Medicine, 346, 522523.
  • Casadevall, N., Nataf, J., Viron, B., Kolta, A., Kiladjian, J.J., Martin-Dupont, P., Michaud, P., Papo, T., Ugo, V., Teyssandier, I., Varet, B. & Mayeux, P. (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. New England Journal of Medicine, 346, 469475.
  • Cavill, I. & Williams, J.D. (2002) Benefits of recombinant human erythropoietin. Lancet, 360, 16061607.
  • Cazzola, M., Mercuriali, F. & Brugnara, C. (1997) Use of recombinant human erythropoietin outside the setting of uremia. Blood, 89, 42484267.
  • Cazzola, M., Messinger, D., Battistel, V., Bron, D., Cimino, R., Enller-Ziegler, L., Essers, U., Greil, R., Grossi, A. & Jager, G. (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood, 86, 44464453.
  • Gabrilove, J.L., Cleeland, C.S., Livingston, R.B., Sarokhan, B., Winer, E. & Einhorn, L.H. (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. Journal of Clinical Oncology, 19, 28752882.
  • Gershon, S.K., Luksenburg, H., Cote, T.R. & Braun, M.M. (2002) Pure red-cell aplasia and recombinant erythropoietin. New England Journal of Medicine, 346, 15841586.
  • Kelley, L.L., Koury, M.J., Bondurant, M.C., Koury, S.T., Sawyer, S.T. & Wickrema, A. (1993) Survival or death of individual proerythroblasts results from differing erythropoietin sensitivities: a mechanism for controlled rates of erythrocyte production. Blood, 82, 23402352.
  • Koury, M.J. & Bondurant, M.C. (1990a) Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science, 248, 378381.
  • Koury, M.J. & Bondurant, M.C. (1990b) Control of red cell production: the roles of programmed cell death (apoptosis) and erythropoietin. Transfusion, 30, 673674.
  • Locatelli, F., Baldamus, C.A., Villa, G., Ganea, A. & Martin de Francisco, A.L. (2002) Once-weekly compared with three-times-weekly subcutaneous epoetin beta: results from a randomized, multicenter, therapeutic-equivalence study. American Journal of Kidney Disease, 40, 119125.
  • Nguyen, T.V. & Trinh, G.N. (2002) Clinical evaluation of once-weekly and three-times-weekly dosings of epoetin alfa in chemotherapy patients: problems of study design and interpretation. Journal of Clinical Oncology, 20, 878.
  • Osterborg, A., Boogaerts, M.A., Cimino, R., Essers, U., Holowiecki, J., Juliusson, G., Jager, G., Najman, A. & Peest, D. (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma: a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood, 87, 26752682.
  • Osterborg, A., Brandberg, Y., Molostova, V., Iosava, G., Abdulkadyrov, K., Hedenus, M. & Messinger, D. (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. Journal of Clinical Oncology, 20, 24862494.
  • Pangalis, G.A., Siakantaris, M.P., Angelopoulou, M.K., Vassilakopoulos, T.P., Dimopoulou, M.N., Kyrtsonis, M.C., Konstantopoulos, K., Tsaftaridis, P., Vaiopoulos, G.A. & Kontopidou, F.N. (2002) Downstaging Rai stage III B-chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin. Haematologica, 87, 500506.
  • Rizzo, J.D., Lichtin, A.E., Woolf, S.H., Seidenfeld, J., Bennett, C.L., Cella, D., Djulbegovic, B., Goode, M.J., Jakubowski, A.A., Lee, S.J., Miller, C.B., Rarick, M.U., Regan, D.H., Browman, G.P. & Gordon, M.S. (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood, 100, 23032320.
  • Tong, E.M. & Nissenson, A.R. (2001) Erythropoietin and anemia. Seminars in Nephrology, 21, 190203.
  • Weiss, L.G., Clyne, N., Divino Fihlho, J., Frisenette-Fich, C., Kurkus, J. & Svensson, B. (2000) The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicentre trial. Swedish Study Group. Nephrology, Dialysis and Transplantation, 15, 20142019.